Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
In an era in which biotechs struggle to get financing and Big Pharma is hungry for new drugs but typically favors deals that delay rewards, Plexxikon Inc. appears to have been dealt a top R&D hand and played its cards exceedingly well. Its strategy has culminated in one of the priciest private buyouts in recent history, its $805 million up-front acquisition by Japan’s Daiichi Sankyo Co.
Ltd.
In an era in which biotechs struggle to get financing and Big
Pharma is hungry for new drugs but typically favors deals that
delay rewards, Plexxikon Inc. appears to
have been dealt a top R&D hand and played its cards exceedingly
well. Its strategy has culminated in one of the priciest private
buyouts in recent history.
Plexxikon chalks up its recent eye-popping $805 million up-front acquisition by Japan's Daiichi Sankyo Co. Ltd. to its truly...
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.